Surmodics (SRDX)
(Delayed Data from NSDQ)
$41.80 USD
+0.02 (0.05%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $41.84 +0.04 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SRDX 41.80 +0.02(0.05%)
Will SRDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SRDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRDX
Surmodics (SRDX) Inks Group Purchasing Agreement With Premier
Why Is Perrigo (PRGO) Down 15.1% Since Last Earnings Report?
SRDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is SurModics (SRDX) Up 21.9% Since Last Earnings Report?
Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
Other News for SRDX
Surmodics secures thrombectomy products agreement with Premier
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
Surmodics awarded thrombectomy products agreement with Premier
Assessing Surmodics: Insights From 5 Financial Analysts
SurModics (SRDX) was downgraded to a Hold Rating at Barrington